PCSK9 inhibitors: An innovative approach to treating hyperlipidemia

Cardiology in Review

Volumn 24, Issue 3, 2016, Pages 141-152

  Sible, Alexandra M ^a   Nawarskas, James J ^a   Anderson, Joe R ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Alirocumab (Praluent); Evolocumab (Repatha); Hyperlipidemia; PCSK9 inhibition

Indexed keywords

ALIROCUMAB; EVOLOCUMAB; ANTILIPEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ARTICLE; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG SAFETY; ELIMINATION HALF-LIFE; FAMILIAL HYPERCHOLESTEROLEMIA; HEALTH CARE COST; HUMAN; HYPERLIPIDEMIA; INFLUENZA; INJECTION SITE REACTION; MYALGIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; VOLUME OF DISTRIBUTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); HYPERLIPIDEMIAS;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; PROPROTEIN CONVERTASE 9;

EID: 84958811460     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0000000000000102     Document Type: Article

References (70)

1. Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA. 2003;100:928-933.
2. Giugliano RP, Sabatine MS. Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? J Am Coll Cardiol. 2015;65:2638-2651.
3. Seidah NG, Awan Z, Chrétien M, et al. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114:1022-1036.
4. Cunningham D, Danley DE, Geoghegan KF, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol. 2007;14:413-419.
5. Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-156.
6. Timms KM, Wagner S, Samuels ME, et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet. 2004;114:349-353.
7. Sun XM, Eden ER, Tosi I, et al. Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum Mol Genet. 2005;14:1161-1169.
8. Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet. 2004;65:419-422.
9. Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272.
10. Hooper AJ, Marais AD, Tanyanyiwa DM, et al. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis. 2007;193:445-448.
11. Mayne J, Dewpura T, Raymond A, et al. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. Clin Chem. 2011;57:1415-1423.
12. Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79:514-523.
13. Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37:161-165.
14. Repatha [package insert]. Thousand Oaks, CA: Amgen Inc; 2015.
15. Praluent [package insert]. Bridgewater, NJ: Sanofi-aventis/Regeneron Pharmaceuticals Inc; 2015.
16. Lunven C, Paehler T, Poitiers F, et al. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects. Cardiovasc Ther. 2014;32:297-301.
17. Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on lowdensity lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol. 2012;60:1888-1898.
18. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366:1108-1118.
19. Ballantyne CM, Neutel J, Cropp A, et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol. 2015;115:1212-1221.
20. Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med. 2015;163:40-51.
21. Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123.
22. Urban D, Pöss J, Böhm M, et al. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol. 2013;62:1401-1408.
23. Stein EA, Kasichayanula S, Turner T, et al. LDL cholesterol reduction with BMS-962476, an adnectin inhibitor of PCSK9: results of a single ascending dose study. J Am Coll Cardiol. 2014;63:A1372.
24. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 2014;383:60-68.
25. Robinson JG, Farnier M, Krempf M, et al.; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489-1499.
26. Kastelein JJP, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholester-olaemia. Eur Heart J. 2015. doi: http://dx.doi. org/10.1093/eurheartj/ehv370.
27. Bays H, Gaudet D, Weiss R, et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J Clin Endocrinol Metab. 2015;100:3140-3148.
28. Bays H, Farnier M, Gaudet D, et al. Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS I and II. Available at: https://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm-469615.pdf. Accessed December 15, 2015.
29. Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015;169:906-915.e13.
30. Cannon CP, Cariou B, Blom D, et al.; ODYSSEY COMBO II Investigators. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36:1186-1194.
31. Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2014;8:554-561
32. Roth EM, Taskinen MR, Ginsberg HN, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. Int J Cardiol. 2014;176:55-61.
33. Moriarty PM, Thompson PD, Cannon CP, et al. ODYSSEY ALTERNATIVE: Efficacy and safety of alirocumab versus ezetimibe, in patients with statin intolerance defined by placebo run-in and statin rechallenge arm. Presented at the American Heart Association Scientific Session 2014, Chicago (Nov 20, 2014).
34. Amgen. PROFICIO: The Evolocumab Clinical Trial Program Backgrounder. Available at: http://www.multivu.com/assets/7061853/documents/7068153-PROFICIO-Backgrounder-FINAL-3-20-14-original.pdf. Accessed January 26, 2016.
35. Stroes E, Colquhoun D, Sullivan D, et al.; GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2541-2548.
36. Koren MJ, Lundqvist P, Bolognese M, et al.; MENDEL-2 Investigators. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2531-2540.
37. Blom DJ, Hala T, Bolognese M, et al.; DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370:1809-1819.
38. Raal FJ, Stein EA, Dufour R, et al.; RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331-340.
39. Raal FJ, Honarpour N, Blom DJ, et al.; TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:341-350.
40. Pfizer. Randomized clinical trial of bococizumab (PF-04950615; RN316) in subjects with hyperlipidemia or mixed dyslipidemia at risk of cardiovascular events (SPIRE-HR). ClinicalTrials.gov [database online]. Bethesda (MD): National Library of Medicine (US). Available at: https://clinicaltrials.gov/ct2/show/NCT01968954. Accessed October 19, 2015.
41. Pfizer. Randomized clinical trial of bococizumab (PF-04950615; RN316) in subjects with hyperlipidemia or mixed dyslipidemia at risk of cardiovascular events (SPIRE-LDL). ClinicalTrials.gov [database online]. Bethesda (MD): National Library of Medicine (US). Available at: https://clinicaltrials.gov/ct2/show/NCT01968967. Accessed October 19, 2015.
42. Pfizer. Randomized clinical trial of bococizumab (PF-04950615; RN316) in subjects with primary hyperlipidemia or mixed dyslipidemia at risk of cardiovascular events (SPIRE-LL). ClinicalTrials.gov [database online]. Bethesda (MD): National Library of Medicine (US). Available at: https://clinicaltrials. gov/ct2/show/NCT02100514. Accessed October 19, 2015.
43. Pfizer. The evaluation of bococizumab (PF-04950615;RN316) in reducing the occurrence of major cardiovascular events in high risk subjects (SPIRE-1). ClinicalTrials.gov [database online]. Bethesda (MD): National Library of Medicine (US). Available at: https://clinicaltrials.gov/ct2/show/NCT01975376. Accessed October 19, 2015.
44. Pfizer. The evaluation of bococizumab (PF-04950615; RN316) in reducing the occurrence of major cardiovascular events in high risk subjects (SPIRE-2). ClinicalTrials.gov [database online]. Bethesda (MD): National Library of Medicine (US). Available at: https://clinicaltrials.gov/ct2/show/NCT01975389. Accessed October 19, 2015.
45. Pfizer. A 52 week study to assess the use of bococizumab (PF-04950615; RN316) in subjects with heterozygous familial hypercholesterolemia (SPIRE-FH). ClinicalTrials.gov [database online]. Bethesda (MD): National Library of Medicine (US). Available at: https://clinicaltrials.gov/ct2/show/NCT01968980. Accessed October 19, 2015.
46. Pfizer. Randomized clinical trial of bococizumab (PF-04950615; RN316) in subjects who are intolerant to statins (SPIRE-SI). ClinicalTrials.gov [database online]. Bethesda (MD): National Library of Medicine (US). Available at: https://clinicaltrials.gov/ct2/show/NCT02135029. Accessed October 19, 2015.
47. Roth EM, Bujas-Bobanovic M, Louie MJ, et al. Patient and physician perspectives on mode of administration of the PCSK9 monoclonal antibody alirocumab, an injectable medication to lower LDL-C levels. Clin Ther. 2015;37:1945-1954.e6.
48. Koren MJ, Giugliano RP, Raal FJ, et al.; OSLER Investigators. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial. Circulation. 2014;129:234-243.
49. Walker J. FDA advises of adverse effects from new cholesterol drugs [Wall Street Journal web site]. Wall Str J. March 7, 2014. Available at: http://www. wsj.com/articles/SB10001424052702304732804579425612487904436. Accessed November 23, 2015.
50. Swiger KJ, Martin SS. PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials. Drug Saf. 2015;38:519-526.
51. Lipinski MJ, Benedetto U, Escarcega RO, et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network metaanalysis. Eur Heart J. 2016;37:536-545.
52. Mbikay M, Sirois F, Mayne J, et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett. 2010;584:701-706.
53. Tice JA, Ollendorf DA, Cunningham C, et al. PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks draft report. Institute for Clinical and Economic Review (ICER). September 8, 2015. Available at: http://cepac.icer-review.org/wp-content/uploads/2015/04/PCSK9-Draft-Report-0908151.pdf. Accessed October 19, 2015.
54. Consumer Reports Best Buy Drugs. Evaluating statin drugs to treat high cholesterol and heart disease: comparing effectiveness, safety, and price. Available at: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.568.4593&rep= rep1&type=pdf. Accessed November 30, 2015.
55. Stone NJ, Robinson JG, Lichtenstein AH, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934.
56. Schulman KA, Balu S, Reed SD. Specialty pharmaceuticals for hyperlipidemia-impact on insurance premiums. N Engl J Med. 2015;373:1591-1593.
57. Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety or alirocumab vs ezetimibe in statin-intolerant patients with a statin rechallenge arm. The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9:758-769.
58. Ahmad Z. Statin intolerance. Am J Cardiol. 2014;113:1765-1771.
59. Banach M, Serban C, Sahebkar A, et al.; Lipid and Blood Pressure Metaanalysis Collaboration Group. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90:24-34.
60. Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380:1995-2006.
61. Roth EM, McKenney JM. ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. Future Cardiol. 2015;11:27-37.
62. Giugliano RP, Desai NR, Kohli P, et al.; LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380:2007-2017.
63. Hirayama A, Honarpour N, Yoshida M, et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statintreated Japanese patients at high cardiovascular risk-primary results from the phase 2 YUKAWA study. Circ J. 2014;78:1073-1082.
64. Mayne J, Dewpura T, Raymond A, et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis. 2008;7:22.
65. Reiner Ž. Management of patients with familial hypercholesterolaemia. Nat Rev Cardiol. 2015;12:565-575.
66. Ricotta DN, Frishman WH: Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia. Cardiol Rev. 2012;20:90-95.
67. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126:2408-2417.
68. Sanofi/Regeneron. ODYSSEY Outcomes: evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab SAR236553 (REGN727). ClinicalTrials.gov [database online]. Bethesda (MD): National Library of Medicine (US). Available at: https://clinicaltrials. gov/ct2/show/NCT01663402. Accessed November 30, 2015.
69. Amgen. Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk. ClinicalTrials.gov [database online]. Bethesda (MD): National Library of Medicine (US). Available at: https://clinicaltrials. gov/ct2/show/NCT01968980. Accessed November 30, 2015.
70. Weinreich M, Frishman WH. Antihyperlipidemic therapies targeting PCSK9. Cardiol Rev. 2014;22:140-146.